multibriefs.com Open in urlscan Pro
199.185.0.153  Public Scan

Form analysis
0 forms found in the DOM

Text Content

This message was sent to ##Email## To advertise in this publication please click
here








May 10, 2022



--------------------------------------------------------------------------------

.TOP NEWS





HOPA is Conducting a Strategic Assessment: Member Opinions Wanted!
Hematology/Oncology Pharmacy Association (HOPA) has started strategic planning
for 2023 and beyond! If you are a current or former HOPA member, we want to hear
from you. Your opinions, feedback, and ideas will help inform how we advance the
hem/onc pharmacy profession and ultimately optimize cancer care moving forward.

Please take a moment to complete the Strategic Assessment that best relates to
your membership status below:
Current Member
Student Member
Former Member






Apply to the HOPA-ASCO Quality Training Program, 2022-2023
This 6-month program from ASCO QTP consists of 10 teams of 3-5 interdisciplinary
members - HOPA is funding on-site attendance for 3 people per team. Take this
opportunity to lead a successful quality improvement activity at your
institution and apply today! It's a chance to:
 * Join an interdisciplinary team of hem/onc pharmacy professionals
 * 6 teams will focus on oral chemotherapy for their projects!
 * Choose and design a Quality Improvement project
 * Implement a full QI project
 * Ultimately, optimize the care of people with cancer

Please take a moment to read the overview of this new 6-month QTP opportunity
and apply here.




--------------------------------------------------------------------------------

.INDUSTRY NEWS





NCCN: Most cancer patients should receive 5 doses of an mRNA COVID-19 vaccine
Cancer Therapy Advisor
The National Comprehensive Cancer Network has released updated recommendations
on COVID-19 vaccination and pre-exposure prophylaxis for patients with cancer.
These recommendations clarify that most patients with active cancer or a recent
history of cancer should receive three doses of an mRNA COVID-19 vaccine as
their primary series.



READ MORE



FDA declines approval for two Chinese cancer drugs
Healthcare Packaging
According to a recent Reuters article, the FDA declined to approve two cancer
treatments developed in China. The drugs in question are Hutchmed’s pancreatic
cancer treatment and a throat cancer medicine developed by Junshi and Coherus.
Single-country trials are responsible for the rejection of the former, while
manufacturing issues held up the latter.



READ MORE


 SPONSORED CONTENT

Promoted by National Comprehensive Cancer Network
Earn BCOP Credits! Access On Demand Presentations from the NCCN Pharmacy Updates
Webinar Series. Register Now for Upcoming Live NCCN Pharmacy Updates on Multiple
Myeloma, Melanoma, and More. New for 2022! Save $10 per BCOP Test by Purchasing
the 12-test Bundle. Earn Up to 6 Contact Hours! View Sessions from the 2022
Breast Cancer Congress. View Presentations from the 2021 Biomarkers Congress and
Earn Up to 6 Contact Hours!


Ovarian cancer is not a silent killer – Recognizing its symptoms could help
reduce misdiagnosis and late detection
Cancer Therapy Advisor
Ovarian cancer is the most deadly of gynecologic tumors. Fewer than 40 percent
of those diagnosed with ovarian cancer are cured, and approximately 12,810
people in the U.S. die from the disease every year. Because no effective
screening test currently exists, 70 percent of people with ovarian cancer are
diagnosed at advanced stages, when chances of cure are poor. Around 60 percent
to 90 percent of people with stage I or II cancer that stays around the ovaries
and pelvis are disease-free 5 years after diagnosis, compared with only 10 to 40
percent of those with stage III or IV cancer that has spread through the abdomen
and beyond.



READ MORE


 PRODUCT SHOWCASE

Available in 2 methods of administration

Learn more about an option that offers healthcare professionals the flexibility
to select the administration method that best suits their practice.


© 2019 Heron Therapeutics, Inc. All rights reserved.
03/19 PP-CV-0184 CINVANTI.com



LEARN MORE


Women are at greater risk for cancer treatment side effects
Cancer Health
Women are more likely than men to experience adverse events related to
chemotherapy, targeted therapy or immunotherapy for cancer, according to study
results published in the Journal of Clinical Oncology.



READ MORE


 PRODUCT SHOWCASE

CALQUENCE Patient Savings Program



The goal of the CALQUENCE Patient Savings Program is to assist eligible,
commercially insured patients with their out-of-pocket costs for CALQUENCE®
(acalabrutinib).




CALQUENCE is a registered trademark of the AstraZeneca group of companies.
©2021 AstraZeneca. All rights reserved. US-51213 Last Updated 4/21



LEARN MORE


Addressing fertility risks and preservation in adolescent and young adult
patients with cancer
Cancer Therapy Advisor
Collaboration and strategic planning across a multidisciplinary team are key to
eliminating potential barriers to fertility discussions with adolescents and
young adult patients, according to research presented at the 47th Annual
Oncology Nursing Society Congress.



READ MORE





 





Optimized chemotherapy infusion schedule increases patient, staff satisfaction
Healio
Mayo Clinic Cancer Center in Phoenix developed and implemented a new system that
allows chemotherapy infusions to be scheduled throughout the day. The initiative
— described in a paper published in JCO Oncology Practice — prevents mid-day
crowding in infusion facilities.



READ MORE


PRODUCT SHOWCASE


PEMFEXY™ (pemetrexed injection) 500 mg/20 mL (25 mg/mL)

Supplied as a Solution in a Multi-Dose Vial
 * No Reconstitution Required
 * Ready-to-Dilute
 * Unique J-Code: J9304
 * NDC: 42367-531-33
 * Supported by the EAGLE CAN™

Reimbursement Support Program


 

LEARN MORE

 

 


Reach Your Prospects Every Week

Thousands of industry professionals subscribe to association news briefs, which
allows your company to push messaging directly to their inboxes and take
advantage of the association's brand affinity.



 

LEARN MORE

 


Real-world data confirm lack of standard care for triple-exposed multiple
myeloma
Hematology Advisor
Real-world data confirm that there is no standard approach for treating patients
with triple-class-exposed relapsed/refractory multiple myeloma, and these
patients continue to have poor outcomes. Researchers found high variability in
treatment regimens for triple-exposed RRMM patients. In addition, these patients
had poor overall survival and progression-free survival. These findings were
presented at the Tandem Meetings 2022 by Michel Delforge, MD, PhD, of
Universitaire Ziekenhuizen Leuven in Belgium.



READ MORE


Standardizing venous port competency among non-oncology nurses helps improve
reduce delay times for patients with cancer
Oncology Nursing News
Oncology nurses with the Yale New Haven Health System successfully developed a
standardized comprehensive training program for non-oncology nurses to achieve
and maintain implanted venous port competency throughout their health care
systems. The program was presented as a poster from the 47th Annual Oncology
Nursing Society Congress.



READ MORE





 





Breaking the shield that protects pancreatic cancer from immunotherapy
UT Southwestern Medical Center via ScienceDaily
Scar-like cells that make up a sizable portion of malignant pancreatic tumors
and shield these cancers from immune attack are derived from mesothelial cells
that line tissues and organs, a new study suggests. The findings could offer a
new strategy to fight pancreatic cancer, a deadly disease for which no truly
effective treatments exist.



READ MORE



Combination of public health interventions may significantly reduce invasive
cancer risk among elderly adults
Pharmacy Times
Combining three affordable public health interventions was found to
significantly reduce the risk of invasive cancers in healthy older adults, in a
study published in Frontiers in Aging. The study investigators found that a
combination of high-dose vitamin D, omega-3s, and a simple home strength
exercise program led to a cumulative reduction in cancer risk by 61 percent in
healthy adults 70 years of age and older.



READ MORE





 





Endoscopy before age 50 years linked to reduced risk for colorectal cancer among
women
Healio
Women who initiated endoscopy screening before age 50 years demonstrated a
significantly reduced risk for colorectal cancer than women who did not undergo
endoscopy, according to study results published in JAMA Oncology. Additionally,
women in whom endoscopy had been initiated between ages 45 and 49 years had a
greater decrease in the total number of colorectal cancer cases through age 60
years, researchers noted.



READ MORE


Novel magnetic therapy complements chemotherapy to enhance breast cancer
treatment outcomes
News-Medical
Breast cancer is the leading cause of cancer-associated death for women
worldwide. While chemotherapy is the mainstream treatment for breast cancer,
more than 50 percent of women undergoing chemotherapy will experience at least
one chemotherapy-related adverse side effect. Sometimes, the side effects could
be so severe that patients need to terminate treatment early or doctors have to
reduce the chemo dosage, and this could worsen their disease. Prolonged exposure
to high doses of chemotherapeutic agents could also result in resistance to
chemotherapy.



READ MORE


Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs
News-Medical
Immune checkpoint inhibitors are widely used to treat a variety of cancers;
however, one serious side effect is the onset of type 1 diabetes. Now,
researchers from Osaka University have discovered that stem cell therapy may
protect against such side effects.



READ MORE


Costs of care and complication rates among patients with hematologic
malignancies undergoing allo-HCT
Hematology Advisor
Patients with hematologic malignancies undergoing inpatient allogeneic
hematopoietic cell transplantation experienced significant health resource use
and costs following allo-HCT, according to research presented at the 2022 Tandem
Meetings.



READ MORE


 
HOPA Bulletin

--------------------------------------------------------------------------------

Connect with HOPA



Hailey Golden, Director of Publishing, MultiView, 469-420-2630 | Download media
kit
Zachary Rasmussen, Content Editor, MultiView, 289-695-5479 | Contribute news

Hematology/Oncology Pharmacy Association
555 E. Wells Street, Suite 1100  |  Milwaukee, WI 53202 
414-918-9800  |  Contact Us  |  www.hoparx.org

Click here to unsubscribe. 

Learn how to add us to your safe sender list so our emails get to your inbox.






ADVERTISE


SUBSCRIBE


PAST ISSUES




 




7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063